Immuno-Biological Laboratories Co., Ltd. (TYO:4570)
888.00
-9.00 (-1.00%)
Nov 18, 2026, 10:30 AM JST
TYO:4570 Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 346 | 300 | 209 | 124 | -280 | -250 |
Depreciation & Amortization | 19 | 18 | 15 | 2 | - | - |
Loss (Gain) From Sale of Assets | - | - | - | - | - | 6 |
Loss (Gain) From Sale of Investments | 11 | - | - | - | 130 | - |
Loss (Gain) on Equity Investments | - | - | - | - | 203 | 152 |
Other Operating Activities | -2 | -2 | -6 | -10 | -8 | -8 |
Change in Accounts Receivable | -2 | 52 | -41 | 32 | -49 | 25 |
Change in Inventory | -85 | -61 | 4 | -3 | -6 | -15 |
Change in Accounts Payable | 9 | -1 | -2 | 5 | 1 | -1 |
Change in Other Net Operating Assets | 5 | -5 | 4 | -17 | 35 | -2 |
Operating Cash Flow | 301 | 301 | 183 | 133 | 26 | -93 |
Operating Cash Flow Growth | 7.50% | 64.48% | 37.59% | 411.54% | - | - |
Investing Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -14 | -33 | -59 | -16 | - | - |
Divestitures | - | - | - | - | 77 | - |
Sale (Purchase) of Intangibles | - | - | - | -2 | - | - |
Investment in Securities | -281 | -83 | 5 | -6 | 5 | -6 |
Other Investing Activities | - | - | 1 | - | 3 | 1 |
Investing Cash Flow | -295 | -116 | -53 | -24 | 30 | -155 |
Financing Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Short-Term Debt Issued | - | 2 | - | 5 | 5 | 105 |
Long-Term Debt Issued | - | - | 20 | 10 | - | 60 |
Total Debt Issued | 7 | 2 | 20 | 15 | 5 | 165 |
Long-Term Debt Repaid | - | -29 | -52 | -14 | -4 | -22 |
Net Debt Issued (Repaid) | -20 | -27 | -32 | 1 | 1 | 143 |
Other Financing Activities | -1 | - | 1 | -1 | -1 | - |
Financing Cash Flow | -76 | -27 | -31 | - | - | 143 |
Net Cash Flow
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Foreign Exchange Rate Adjustments | - | - | -2 | 2 | 2 | 1 |
Miscellaneous Cash Flow Adjustments | 2 | -1 | -2 | 1 | 54 | 2 |
Net Cash Flow | -68 | 157 | 95 | 112 | 112 | -102 |
Free Cash Flow
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 287 | 268 | 124 | 117 | 26 | -93 |
Free Cash Flow Growth | 25.88% | 116.13% | 5.98% | 350.00% | - | - |
Free Cash Flow Margin | 26.52% | 26.69% | 12.80% | 14.34% | 3.28% | -14.37% |
Free Cash Flow Per Share | 30.82 | 28.78 | 13.31 | 12.56 | 2.79 | -9.99 |
Levered Free Cash Flow | 143 | 151 | 55 | 64.13 | 119.88 | -192.25 |
Unlevered Free Cash Flow | 143.63 | 151.63 | 55.63 | 64.75 | 120.5 | -192.25 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 1 | 1 | 3 | 3 | 1 | - |
Cash Income Tax Paid | 4 | 5 | 5 | 9 | 8 | 8 |
Change in Working Capital | -73 | -15 | -35 | 17 | -19 | 7 |